SAN FRANCISCO, Nov. 09, 2022 (GLOBE NEWSWIRE) — Hagens Berman Urges R1 RCM Inc. (NASDAQ:RCM) Investors who have suffered significant losses Submit your losses now.

Visit: https://www.hbsslaw.com/investor-fraud/RCM
Contact a lawyer now: [email protected]
844-916-0895

R1 RCM Inc. (NASDAQ:RCM) Investigation:

The investigation focuses on R1 RCM’s previous assurances that it has successfully initiated and enhanced recently contracted businesses, including Pediatrix (Mednax).

Doubts about R1 RCM’s assurances surfaced on November 8, 2022, when the company shocked the market with a net loss of $29.5 million for the third quarter of 2022, compared to a net income of $17 million for the same period of the previous year. Management attributed the dismal results in large part to lower income from incentive fees. During the results conference call, management announced that the company had identified fluctuations in key performance indicator (KPI) metrics at two operational partner customers that the company began onboarding in 2021. Management stated that these customers presented “unique complexities” resulting in R1 RCM is taking longer to meet expected performance targets.

In response to analyst inquiries about these complexities, management specifically identified Pediatrix as one of the impacted customers, stating that Pediatrix had a change in their host systems strategy “that initially left us unable to deploy our technology.”

Concurrent with the dismal financial results, R1 RCM also announced that its CEO (Joseph Flanagan) is leaving his position.

This news caused the price of R1 RCM shares to fall by almost 50% on November 8, 2022.

“We are focused on investor losses and whether R1 RCM misleadingly touted recent contract wins while concealing larger deployment issues on the same customer systems,” said Reed Kathrein, the partner at Hagens Berman who led the investigation.

If you have invested in R1 RCM and are suffering significant losses or have knowledge that can help the firm…